{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:18:44Z","timestamp":1785147524663,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clinthera.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:12:34Z","timestamp":1746789154000},"page":"484-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association Between Anticoagulants and Interacting Drugs and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation: Case-Control Study in SIDIAP, Catalonia, Spain"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-9233","authenticated-orcid":false,"given":"M.","family":"Giner-Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Carrasco-Ribelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Castel Llobet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cereza Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.003_bib0001","unstructured":"Departament de Salut G de C. CIM-10-MC\/SCP [Internet]. Available from: https:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/registres-catalegs\/catalegs\/diagnostics-procediments\/cim-10-mc-scp\/."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0002","unstructured":"Boehringher Ingelheim International GmbH. London (United Kingdom): European Medicines Agency (EMA); 2008. Pradaxa Summary of Product Characteristics [Internet]. 2013 [cited 2019 Aug 5]. p. Available at: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0003","unstructured":"WHO collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2025 [Internet]. 2025. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0004","first-page":"1","article-title":"Criterios y recomendaciones generales para el uso de anticoagulantes orales directos (ACOD) en la prevenci\u00f3n del ictus y la embolia sist\u00e9mica en pacientes con fibrilaci\u00f3n auricular no valvular. [Internet]","year":"2012","journal-title":"AEMPS (actualizaci\u00f3n 2024)"},{"issue":"11","key":"10.1016\/j.clinthera.2025.04.003_bib0005","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1111\/bcp.15478","article-title":"Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis","volume":"88","author":"Ahn","year":"2022","journal-title":"Br J Clin Pharmacol [Internet]"},{"issue":"6","key":"10.1016\/j.clinthera.2025.04.003_bib0006","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug\u2013drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.clinthera.2025.04.003_bib0007","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3390\/pharmaceutics14071410","article-title":"Drug\u2013Drug interactions with oral anticoagulants as potentially inappropriate medications: prevalence and outcomes in elderly patients in primary care and hospital settings","volume":"14","author":"Bories","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0008","article-title":"Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation","author":"Bortman","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0009","article-title":"Servei Catal\u00e0 de la Salut","year":"2022","journal-title":"Conjunt m\u00ednim b\u00e0sic de dades (CMBD) [Internet]"},{"issue":"3","key":"10.1016\/j.clinthera.2025.04.003_bib0010","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/08971900211059411","article-title":"Impact of drug interactions on major bleed rates in patients taking direct oral anticoagulants","volume":"36","author":"Cook","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0011","doi-asserted-by":"crossref","unstructured":"De Burgos-Gonzalez A, Huerta C, Mar\u00eda |, et al. Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain. 2022 [cited 2023 Jun 15]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5525.","DOI":"10.1002\/pds.5525"},{"issue":"3","key":"10.1016\/j.clinthera.2025.04.003_bib0012","article-title":"Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists","volume":"2022","author":"Dongre","year":"2022","journal-title":"Glob Cardiol Sci Pract [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0013","article-title":"Rivaroxaban","year":"2012","journal-title":"Summary of product characteristics [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0014","unstructured":"European Medicines Agency. Summary of product characteristics Eliquis. [Internet]. 2013 [cited 2016 Sep 21]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0015","article-title":"Edoxaban","year":"2016","journal-title":"Summary of product characteristics [Internet]"},{"issue":"2","key":"10.1016\/j.clinthera.2025.04.003_bib0016","first-page":"1","article-title":"Complicacions hemorr\u00e0giques en pacients tractats amb tramadol i anticoagulants orals directes","volume":"21","year":"2023","journal-title":"Butllet\u00ed de Farmacovigil\u00e0ncia de Catalunya [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0017","first-page":"1","article-title":"Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front Pharmacol [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0018","article-title":"Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in Catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front Pharmacol [Internet]"},{"issue":"10","key":"10.1016\/j.clinthera.2025.04.003_bib0019","article-title":"Nonvitamin K anticoagulants: risk of bleeding when interacting with other medications: A cohort study from Medicare","volume":"47","author":"Gomez-Lumbreras","year":"2024","journal-title":"Clin Cardiol [Internet]"},{"issue":"6","key":"10.1016\/j.clinthera.2025.04.003_bib0020","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinthera.2025.04.003_bib0021","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J [Internet]"},{"issue":"8","key":"10.1016\/j.clinthera.2025.04.003_bib0022","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/heartjnl-2021-319503","article-title":"Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants","volume":"108","author":"Holt","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1248\/bpb.b20-00791","article-title":"Comprehensive exploration of medications that affect the bleeding risk of oral anticoagulant users","volume":"44","author":"Kawano","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0024","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","author":"Langan","year":"2018","journal-title":"Bmj [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0025","first-page":"3","article-title":"Use of tramadol and the risk of bleeding complications in patients on oral anticoagulants: a systematic review and meta-analysis","volume":"1","author":"L\u00e9vy","year":"2022","journal-title":"Eur J Clin Pharmacol [Internet]"},{"issue":"9816","key":"10.1016\/j.clinthera.2025.04.003_bib0026","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6","article-title":"Atrial fibrillation","volume":"379","author":"Lip","year":"2012","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0027","unstructured":"Micromedex. Acenocoumarol drug-drug interactions. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowDrugInteractionsResults. 2023."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0028","unstructured":"Micromedex. Warfarin drug-drug interactions. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowDrugInteractionsResults. 2023."},{"issue":"1","key":"10.1016\/j.clinthera.2025.04.003_bib0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/07853890.2021.2017474","article-title":"Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis","volume":"54","author":"Nochaiwong","year":"2022","journal-title":"Ann Med [Internet]"},{"issue":"5","key":"10.1016\/j.clinthera.2025.04.003_bib0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/jcph.2003","article-title":"Risk of bleeding associated with nonsteroidal anti-inflammatory drug use in patients exposed to antithrombotic therapy: a case-crossover study","volume":"62","author":"Paternoster","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.04.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3593","article-title":"Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function","volume":"3","author":"Pham","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0032","unstructured":"Programa d\u2019harmonitzaci\u00f3 farmacoterap\u00e8utica. Pautes per a l\u2019harmonitzaci\u00f3 de l\u2019\u00fas d\u2019anticoagulants orals per a la prevenci\u00f3 de l\u2019ictus i l\u2019emb\u00f2lia sist\u00e8mica en pacients amb fibril\u00b7laci\u00f3 auricular. Barcelona: Servei Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya; 2018. [Internet]. 2018. Available from: http:\/\/catsalut.gencat.cat\/ca\/detalls\/articles\/PautesACO_FA."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0033","first-page":"1","article-title":"Data Resource Profile: the Information System for Research in Primary Care (SIDIAP)","author":"Recalde","year":"2022","journal-title":"Int J Epidemiol [Internet]"},{"issue":"3","key":"10.1016\/j.clinthera.2025.04.003_bib0034","first-page":"505","article-title":"The impairment in kidney function in the oral anticoagulation era","volume":"35","author":"Scicchitano","year":"2021","journal-title":"A Pathophysiological Insight"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","article-title":"Association between concurrent use of Amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation","volume":"186","author":"Shurrab","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0036","unstructured":"SIDIAP. SIDIAP. Information system for research in Primary Care [Internet]. SIDIAP. 2023. Available from: http:\/\/www.sidiap.org\/index.php\/en."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0037","unstructured":"Ivan H. Stockely. Interacciones farmacol\u00f3gicas. Pharma Editores, SL. Barcelona, Spain; 2004."},{"key":"10.1016\/j.clinthera.2025.04.003_bib0038","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","article-title":"Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs","volume":"126","author":"St\u00f6llberger","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2025.04.003_bib0039","doi-asserted-by":"crossref","unstructured":"St\u00f6llberger C, Schneider B, Finsterer J. Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events. [Internet]. 2023 Apr 3 [cited 2023 Jun 16];1\u201316. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/17512433.2023.2187376.","DOI":"10.1080\/17512433.2023.2187376"},{"issue":"3","key":"10.1016\/j.clinthera.2025.04.003_bib0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/ehjcvp\/pvz035","article-title":"Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs","volume":"6","author":"Wang","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother [Internet]"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:02:54Z","timestamp":1762246974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0149291825001225"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Anticoagulants and Interacting Drugs and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation: Case-Control Study in SIDIAP, Catalonia, Spain","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}